Provided by Tiger Trade Technology Pte. Ltd.

HUTCHMED

22.340
-0.620-2.70%
Volume:789.50K
Turnover:17.62M
Market Cap:19.48B
PE:42.96
High:22.820
Open:22.820
Low:22.100
Close:22.960
52wk High:26.000
52wk Low:15.570
Shares:872.00M
HK Float Shares:872.00M
Volume Ratio:0.19
T/O Rate:0.09%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.520
ROE:1.46%
ROA:-1.24%
PB:1.97
PE(LYR):42.96
PS:4.52

Loading ...

HUTCHMED to Showcase Positive Phase III Data on Savolitinib–Osimertinib Combination at ESMO 2026

Bulletin Express
·
Sep 24

Hutchmed Says Saffron Phase III Trial of Savolitinib-Osimertinib Combo Beats Chemo in EGFR-Mutant NSCLC After Osimertinib Progression

Reuters
·
Sep 24

BofA Adjusts Price Target on HUTCHMED (China) to $18 From $16, Keeps Buy Rating

MT Newswires Live
·
Sep 21

Market Chatter: US Considers Rules Allowing American Investment in Chinese Drugs

MT Newswires Live
·
Sep 21

HUTCHMED Surges in Late Hong Kong Trading as GSK Licensing Deal Signals Clear Global Expansion Path

Stock News
·
Sep 17

CICC Lifts HUTCHMED Price Target to HK$28, Reaffirms Outperform Rating

Stock News
·
Sep 08

UBS Flags Strong H1 Sales for Chinese Biotech Despite Regulatory Headwinds, Eyes Late-Year Catalysts

Stock News
·
Sep 07

Citigroup Lifts HUTCHMED Price Target to HK$39, Maintaining Buy and High-Risk Call

Stock News
·
Sep 04

HUTCHMED Surges Over 6% on $1.295 Billion GSK Deal, Validating Global Potential of Its ATTC Platform

Stock News
·
Sep 04

Movement Alert|HUTCHMED Rises 5.3% in Regular Trading, GSK Licensing Deal Worth Up to $1.295 Billion Continues to Lift Shares

Market Focus
·
Sep 04

HUTCHMED Surges 14% on $1.295 Billion Licensing Deal with GSK for Novel Dual-Targeting Cancer Therapy

Deep News
·
Sep 03

Asian Market Selloff Triggered by Yen Rally While Precious Metals Rebound Lifts Mining Sector

Stock News
·
Sep 03

Hong Kong Stocks Fall on Thursday, Amid Bond Selloff, Rate Fears; HUTCHMED Jumps 14%

MT Newswires Live
·
Sep 03

Hutchmed Jumps Most in Near 4 Years on GSK Licensing Deal

Reuters
·
Sep 03

UK Stocks-Factors to Watch on September 3

Reuters
·
Sep 03

Hutchmed China Ltd - Hutchmed Licenses Kras-Egfr-Antibody to GSK

THOMSON REUTERS
·
Sep 03

Sweden's Integrum Q1 Sales Rise on Higher S1 Surgeries

Reuters
·
Sep 03

Movement Alert|HUTCHMED Rises 8.36% in Regular Trading, Signs Global Licensing Agreement with GSK for KRAS-Targeted Antibody Drug Conjugate

Market Focus
·
Sep 03

Hutchmed (China) Signs Exclusive Licensing Deal with GSK for Investigational Cancer Drug

Reuters
·
Sep 03

HUTCHMED Grants GSK Ex-China Rights to KRAS-EGFR ATTC in Deal Worth Up to US$1.30 Billion

Bulletin Express
·
Sep 03